About us and our Products:
History
History
History
A New Approach to Drug Discovery
For over 80 years, the search for the “one-cure-fits-all” drugs has dominated R&D. We’ve been chasing unicorns—drugs that work universally for every patient diagnosed with a certain condition, regardless of individual differences.
Take cancer, for example.
Nearly 80% of our products are used in cancer res
A New Approach to Drug Discovery
For over 80 years, the search for the “one-cure-fits-all” drugs has dominated R&D. We’ve been chasing unicorns—drugs that work universally for every patient diagnosed with a certain condition, regardless of individual differences.
Take cancer, for example.
Nearly 80% of our products are used in cancer research. Yet, despite multiple decades of effort, any universal cure remains elusive.
Why? Because we are all different. Each of us carries a unique combination of biomarkers, making the idea of a single cure akin to finding a needle in a haystack—statistically improbable, if not impossible.
(A case study at the end of our pitch deck below will illustrate this challenge clearly.)
Pharmaceutical companies have followed this approach for so long that it has become ingrained in the industry’s as well as people's mindset.
History
History
But we, along with a growing number of researchers, see things differently.
Rather than searching for a single cure for the entire population, we focus on dividing that population into subgroups, based on similar biomarker profiles. And that is just a start!
By identifying treatments that work for a specific subgroup, researchers can
But we, along with a growing number of researchers, see things differently.
Rather than searching for a single cure for the entire population, we focus on dividing that population into subgroups, based on similar biomarker profiles. And that is just a start!
By identifying treatments that work for a specific subgroup, researchers can then expand the approach, gradually testing whether a treatment remains effective as biomarker variations increase.
This shift in strategy, from blind & random drug discovery to a precision-based, biomarker-driven approach, is at the foundation of our work.
It is also known as the individualization of research samples.
Our mission is to provide such critical clinical biomarker data at the early discovery and preclinical research stages.
History
Instead of a trial-and-error journey in complete darkness, our approach illuminates the path forward, dramatically increasing the likelihood of success.
Currently, 80+% of drug candidates and the research therein fail reproducibility and clinical translation. And potential cures may have been discarded wrongfully!
We strongly believe t
Instead of a trial-and-error journey in complete darkness, our approach illuminates the path forward, dramatically increasing the likelihood of success.
Currently, 80+% of drug candidates and the research therein fail reproducibility and clinical translation. And potential cures may have been discarded wrongfully!
We strongly believe that by integrating biomarker intelligence early in the process, we can turn the tide and significantly improve outcomes.
This is the future of drug discovery. And First Choice Bio is leading the way.
First Choice Bio, Inc. is currently raising funds to further develop these groundbreaking technologies and set up their own collection centers annex laboratories across the US and beyond to help research bridge that 80+% "valley of death" in the interest of all mankind!
Check out our Pitch Deck and Executive Summary below and
Come and Join us!